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Abstract
Objective To determine the potential impact of on-site CT-derived fractional flow reserve (CT-FFR) on the diagnostic efficiency
and effectiveness of coronary CT angiography (CCTA) in patients with obstructive coronary artery disease (CAD) on CCTA.
Methods This observational cohort study included patients with suspected CAD who had been randomized to cardiac CT in the
CRESCENT I and II trials. On-site CT-FFR was blindly performed in all patients with at least one ≥ 50% stenosis on CCTA and
no exclusion criteria for CT-FFR. We retrospectively assessed the effect of adding CT-FFR to the CT protocol in patients with a
stenosis ≥ 50% on CCTA in terms of diagnostic effectiveness, i.e., the number of additional tests required to determine the final
diagnosis, reclassification of the initial management strategy, and invasive coronary angiography (ICA) efficiency, i.e., ICA rate
without ≥ 50% CAD.
Results Fifty-three patients out of the 372 patients (14%) had at least one ≥ 50% stenosis on CCTA ofwhom 42/53 patients (79%)
had no exclusion criteria for CT-FFR. CT-FFR showed a hemodynamically significant stenosis (≤ 0.80) in 27/53 patients (51%).
The availability of CT-FFRwould have reduced the number of patients requiring additional testing by 57%-points comparedwith
CCTA alone (37/53 vs. 7/53, p < 0.001). The initial management strategy would have changed for 30 patients (57%, p < 0.001).
Reserving ICA for patients with a CT-FFR ≤ 0.80 would have reduced the number of ICA following CCTA by 13%-points
(p = 0.016).
Conclusion Implementation of on-site CT-FFR may change management and improve diagnostic efficiency and effectiveness in
patients with obstructive CAD on CCTA.
Key Points
• The availability of on-site CT-FFR in the diagnostic evaluation of patients with obstructive CAD on CCTA would have
significantly reduced the number of patients requiring additional testing compared with CCTA alone.
• The implementation of on-site CT-FFR would have changed the initial management strategy significantly in the patients with
obstructive CAD on CCTA.
• Restricting ICA to patients with a positive CT-FFR would have significantly reduced the ICA rate in patients with obstructive
CAD on CCTA.
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Abbreviations
CAD Coronary artery disease
CCTA Coronary computed tomography angiography
CRESCENT Computed Tomography vs. Exercise
Testing in Suspected Coronary Artery Disease
CT-FFR Computed tomography–derived
fractional flow reserve
FFR Fractional flow reserve
ICA Invasive coronary angiography
MACE Major adverse cardiovascular events
Introduction
Coronary CT angiography (CCTA) has become a recom-
mended diagnostic test in the management of coronary artery
disease (CAD) [1]. Although CCTA effectively rules out ob-
structive CAD, it is limited in the ability to assess the hemo-
dynamic importance of angiographic lesions [2]. Because the
anatomic stenosis severity is a weak predictor of hemodynam-
ic significance, functional evaluation is recommended for
therapeutic decision-making [3]. CT-derived fractional flow
reserve (CT-FFR) can compute FFR values from standard
CCTA images without requiring additional testing and radia-
tion exposure, and has shown a good correlation and agree-
ment with invasive FFR in several studies [4–7]. On-site CT-
FFR software enables CT-FFR analyses on standard worksta-
tion without transferring CT images [8, 9]. Additionally, on-
site CT-FFR computation through interpretation of anatomical
features (based on machine-learning algorithms) can, in con-
trary to computational fluid dynamic–based algorithms, be
performed in several seconds [8, 10]. A comprehensive qual-
itative analysis of CCTA with on-site CT-FFR could provide
all essential information for clinical decision-making and re-
duce the need for further noninvasive and invasive testing.
The CRESCENT I and II studies (Computed Tomography
vs. Exercise Testing in Suspected Coronary Artery Disease)
are pragmatic randomized controlled trials that assessed the
clinical effectiveness of a tiered cardiac CT approach against
standard functional testing [11, 12]. The tiered cardiac CT
protocol included a calcium scan, followed by CCTA if calci-
um was detected. Patients enrolled in CRESCENT II with at
least one ≥ 50% stenosis on CCTA additionally underwent CT
myocardial perfusion imaging (CT-MPI). In this study, we
performed an on-site CT-FFR analysis using a machine-
learning algorithm in patients with suspected CAD and a
≥ 50% stenosis on CCTA who were enrolled in the
CRESCENT I and II cohorts, to assess the potential impact
of this functional CCTA application on the diagnostic
efficiency and effectiveness of CCTA in patients with obstruc-
tive CAD on CCTA.
Methods
Study population
This study involved the assessment of CCTA and CT-FFR
data from patients who were randomized to cardiac CT in
the CRESCENT I and II trials. The CRESCENT I and II
studies are pragmatic randomized controlled trials that
assessed the clinical effectiveness of a tiered cardiac CT ap-
proach compared with the standard diagnostic work-up using
functional testing in patients with suspected CAD. The
methods and primary results have been reported previously
[11, 12]. In brief, 618 patients with stable chest pain and
suspected CAD were prospectively enrolled in the
CRESCENT I and II trials at 6 hospitals in the Netherlands.
Patients were randomly assigned to CTor functional testing in
a 2:1 ratio in the CRESCENT I trial and in a 1:1 ratio in the
CRESCENT II trial. Exclusion criteria in both trials were a
history of known CAD and an invasive coronary angiography
(ICA) or stress test performed < 1 year ago. Additional exclu-
sion criteria in CRESCENT II were renal impairment, contrast
allergy, atrial fibrillation, or other CCTA-specific contraindi-
cations. Results of downstream diagnostic and therapeutic
procedures were collected from medical records up to 1 year
in the CRESCENT I trial and up to 6 months in the
CRESCENT II trial. The studies were approved by the med-
ical ethics committees at each participating site, and all partic-
ipants provided informed consent.
Tiered cardiac CT strategy
All participants in the cardiac CT group of the CRESCENT
trials underwent a non-contrast-enhanced coronary calcium
scan (Fig. 1). In patients with a low or intermediate probability
of CAD by Diamond and Forrester [13], the absence of calci-
um excluded obstructive CAD and obviated the need for fur-
ther testing. Patients with a positive calcium score (> 0), as
well as patients with a high pre-test probability of CAD (re-
gardless of the calcium score), subsequently underwent CCTA
to detect obstructive CAD. In the CRESCENT I trial, patients
with a calcium score > 400 were deferred from CCTA but
underwent stress testing or ICA at the discretion of the treating
physician. Patients enrolled in the CRESCENT II trial with a
≥ 50% stenosis on CCTA underwent an adenosine-stress dy-
namic CT-MPI in the same session. Patients received
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sublingual nitroglycerin before CCTA and if indicated (heart
rate > 65/min) and clinically acceptable beta-blockers. All
sites were equipped with 64-slice or more advanced CT tech-
nology. Interpretation of the CT scans combined with avail-
able clinical data, as well as subsequent clinical management
decisions, was performed by local physicians, in accordance
with international guidelines [14].
CT-FFR analysis
According to European guidelines, functional assessment is
recommended in patients with stable chest pain and stenosis
≥ 50% on CCTA to correlate chest pain symptoms with coro-
nary atherosclerotic ischemia [1]. Therefore, all CCTA exam-
inations performed as part of the CRESCENT trials were re-
analyzed with CT-FFR for the purpose of the current study if
at least one ≥ 50% stenosis was present to assess the potential
clinical impact of CT-FFR on the diagnostic work-up of
CCTA (Table 1; Fig. 1). Exclusion criteria were coronary total
occlusion, insufficient image quality, or disrupted CCTA im-
ages. Image quality was evaluated based on a 4-point Likert
scale: 1 nondiagnostic; 2 impaired image quality, differentia-
tion of coronary artery wall possible with reduced confidence;
3 adequate, reduced image quality due to artifacts without
limiting coronary artery wall differentiation; 4 excellent, no
artifacts present and clear differentiation of the coronary artery
wall. The CT-FFR analysis was performed using a validated
machine-learning based CT-FFR software prototype (cFFR
version 2.1, Siemens Healthineers; not currently commercial-
ly available) [6]. The coronary artery tree was semi-
automatically segmented to generate a 3D coronary model.
All vessels and side branches of sufficient image quality and
a vessel diameter of at least 1.5 mm were included. The left
ventricle myocardial mass was automatically determined from
the CT images to estimate the resting total coronary blood
flow. Each point on the coronary artery tree was analyzed
and CT-FFR was derived based on a combination of pattern
recognition and computational learning. Ischemic obstructive
Fig. 1 Cardiac CT algorithm and
results. Patient flow diagram of
cardiac CT and CT-derived frac-
tional flow reserve (CT-FFR), and
its results. High-risk ischemia is
defined as 3-vessel disease, left
main disease, or proximal left an-
terior descending coronary dis-
ease on coronary CT angiography
(CCTA) and at least one hemo-
dynamically relevant stenosis de-
fined by CT-FFR ≤ 0.80. CAD =
coronary artery disease
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CADwas defined as a stenosis ≥ 50% on CCTAwith a lesion-
specific CT-FFR ≤ 0.80, measured 20 mm downstream of the
stenosis.
Outcomes
The impact of CT-FFR on clinical management of patients
with a ≥ 50% stenosis on CCTAwas evaluated by comparing
the diagnostic efficiency and effectiveness of the observed
CCTA strategy with the proposed CT-FFR strategy. The clin-
ical efficiency outcomes included the time to diagnosis from
the first outpatient visit until the first test that led to the final
diagnosis or the final test that ruled out CAD. Additional tests
included all noninvasive tests, including CT-MPI, and ICA to
diagnose CAD after the initial tests (calcium scan and/or
CCTA). Since CT-FFR was simulated to be part of the CT
analysis, results were presumed to be available on the same
day as the CCTA results for the diagnostic evaluation. The
availability of both anatomical and functional information
provided by CCTA and CT-FFR was presumed to result in a
final diagnosis and management strategy, which would have
made all observed additional tests for determining the final
diagnosis or management strategy unnecessary. Initial man-
agement strategy consisted of the following options: optimal
medical therapy, additional testing required, and revasculari-
zation. The CT-FFR-based clinical management decisions
were determined based solely on the CCTA and CT-FFR find-
ings, in line with recommendations from international
Table 1 Demographics and
baseline patient characteristics Cardiac CT (n = 372)
Characteristics
Mean age (years) 56 ± 11
Female sex (%) 197 (53%)
History (%)
Transient ischemic attack or
cerebrovascular accident
16 (4%)
Peripheral artery disease 12 (3%)
Cardiac risk factors (%)
Current or past smoker 125 (34%)
Hypertensiona 192 (52%)
Dyslipidemiab 179 (48%)
Diabetes mellitusc 65 (17%)
Family history of ischemic heart disease 139 (37%)
Body mass index (kg/m2) ≥ 25† 258 (69%)
Presenting chest pain symptoms (%)
Typical angina 106 (28%)
Atypical angina 184 (49%)
Non-anginal complaints 81 (22%)
Unknown 1 (< 1%)
Pre-test probability – Diamond Forrester (%)d 54 (22–79)
Pre-test probability – genders (%) 37 (20–58)
Medication use (%)††
Statins or other antiplatelet agents 172 (46%)
Antiplatelets and/or oral anticoagulants 118 (32%)
ACEi and/or ARB 77 (21%)
Diuretics 45 (12%)
Beta-blockers 100 (27%)
Calcium antagonists 41 (11%)
Nitrates, oral, or sublingual 22 (6%)
Patient characteristics are presented as mean ± SD, median with 25th–75th percentile, and totals with percentages.
a Hypertension: systolic > 150 mmHg, diastolic > 90 mmHg, or medication use. b Dyslipidemia: total cholesterol
> 5 mmol/L, low-density lipoprotein > 3 mmol/L, or lipid-lowering medication use. c Diabetes mellitus: plasma
glucose > 11 mmol/L, or medication use. d Diamond and Forrester criteria [9]. †Missing data of 7 patients,
††Missing data of 2 patients. ACEi angiotensin-converting-enzyme inhibitors, ARB angiotensin-II receptor
blockers
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guidelines [14]. Information concerning downstream diagnos-
tic testing, as part of the trials or otherwise, as well as clinical
outcome data were withheld at the time of CT-FFR-based
reassessment of patient management. High-risk obstructive
CAD (≥ 50% stenosis) on CCTA, defined as 3-vessel disease,
left main disease, or proximal left anterior descending coro-
nary disease, with evidence of ischemia, defined as at least one
lesion-specific CT-FFR ≤ 0.80, was considered an indication
for ICA referral in accordance with European guidelines as
revascularization is of potential prognostic benefit in those
patients [15]. All patients without high-risk obstructive CAD
on CCTA or without CT-FFR ≤ 0.80 were considered eligible
for initial medical treatment. Diagnostic effectiveness out-
comes included the number of patients having ICA, ICAwith-
out ≥ 50% stenosis, and ICA leading to revascularization.
When CT-FFR was not analyzed due to presence of contrain-
dications (coronary total occlusions, insufficient CT image
quality, or disrupted CCTA images), outcomes of the observed
CCTA strategy and the proposed CT-FFR strategy were pre-
sumed to be the same. Major adverse cardiac events (MACE)
included death, nonfatal myocardial infarction, unstable angi-
na requiring revascularization, and stroke.
Statistics
Categorical variables are represented as totals and percentages
and continuous variables are represented as means ± standard
deviations or median with 25th–75th percentiles. McNemar’s
test and Wilcoxon signed-rank test were used to test the dif-
ferences in categorical and continuous variables between the
observed CT strategy and the proposed CT-FFR strategy. Chi-
squire test was used to test the differences in ICA leading to
revascularization between the observed CT strategy and the
proposed CT-FFR strategy. A two-sided p value of < 0.05 was
considered statistically significant. Statistical analyses were
performed using SPSS (version 25, IBM Corp).
Results
Study population
A total of 370 out of 372 patients (99%) randomized to cardiac
CT (age 56 ± 11 years, 53% women) had undergone a non-
contrast-enhanced coronary calcium scan as their first diag-
nostic test in the CRESCENT trials (Table 1; Fig. 1). In 150
patients (41%), CAD had been excluded based on the absence
of coronary calcium and thus had not undergone CCTA as per
study protocol. Of the remaining cohort, 193 patients had
undergone CCTA, after exclusion of 25 patients with a calci-
um score > 400 and 9 patients with contraindications to CCTA
(CRESCENT I). CCTA showed ≥ 50% stenosis in 53 patients
(27%), including 18 patients (9%) with high-risk obstructive
CAD (3-vessel disease, left main disease, or proximal left
anterior descending coronary disease).
CT-FFR findings
The CT-FFR analysis was calculated in 42/53 patients (79%)
with obstructive CAD (≥ 50% stenosis) on CCTA, as CT-FFR
could not be performed in 7 patients with a coronary total
occlusion, 3 patients with insufficient CCTA image quality,
and 1 patient with a disrupted CCTA dataset (Figs. 1 and 2).
CT-FFR ≤ 0.80was present in one ormore coronary arteries in
27/53 patients (51%), including 9 patients (17%) with high-
risk obstructive CAD on CCTA.
Potential impact of CT-FFR on diagnostic efficiency
and medical management
A total of 54 noninvasive and invasive additional tests, includ-
ing 29 CT-MPI studies, had been requested in 37/53 patients
(70%) with obstructive CAD onCCTA to reach a final clinical
diagnosis and determine the management designation of med-
ical management or revascularization (Fig. 3). In 16 patients
(30%), the final clinical diagnosis had been reached based on
CCTA alone and 13 patients had been treated with optimal
medical therapy and 3 patients had been directly referred for
coronary intervention. CT-FFR was performed in 30 out of 37
patients in whom additional testing had been required to reach
the final diagnosis. The availability of CT-FFR in the diagnos-
tic evaluation of patients with obstructive CAD on CCTA
would have reduced the number of patients requiring addition-
al testing by 57%-points compared with CCTA alone (from
70% (37/53) to 13% (7/53), p < 0.001), and would have ren-
dered 42/54 (78%, p < 0.001) of the additional tests no longer
necessary. This included 18 diagnostic ICAs and 24 noninva-
sive tests (22 CT-MPI and 2 SPECT studies). Seven patients
(13%) with obstructive CAD would have still required addi-
tional testing because CT-FFR could not be performed.
Consequently, the implementation of CT-FFR would have
reclassified the initial management strategy in 30/53 patients
(57%, p < 0.001) with obstructive CAD on CCTA (Fig. 4).
Twenty-three patients (43%) would have been reclassified
from requiring additional testing (n = 17) or revascularization
(n = 6) to optimal medical therapy. Of these patients, ICA had
been performed in 12 patients during the course of the
CRESCENT trials of whom no one showed high-risk obstruc-
tive CAD (3-vessel disease, left main disease, or proximal left
anterior descending coronary disease with objective ische-
mia). Furthermore, CT-FFRwould have reclassified 7 patients
(13%) from requiring additional testing to revascularization.
Of these patients, ICA had been performed in 6 patients during
the course of the CRESCENT trials of which 4 patients
showed high-risk obstructive CAD.
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Potential impact of CT-FFR on ICA
and revascularization
At 6–12 months follow-up, 32/53 patients (60%) with ob-
structive CAD on CCTA had undergone ICA. Restricting
ICA to patients with a positive CT-FFR (≤ 0.80) would have
reduced the ICA rate by 13%-points: from 60% (32/53) to
47% (25/53, p = 0.016). CT-FFR would have avoided an
ICAwithout ≥ 50% stenosis in 4 out of 7 patients and would
have resulted in a rate of ICA leading to revascularization of
88% (22/25) compared with 78% (25/32) with CCTA alone
(p = 0.487). In one patient who did not undergo ICA, an ab-
normal CT-FFR result would have indicated a need for cath-
eterization/revascularization. Three patients with FFR > 0.80
were revascularized during the course of the CRESCENT
trials; all of whom had low-risk obstructive CAD on CCTA
and were initially treated with optimal medical therapy based
on CCTA results. One patient had a left bundle branch block
on electrocardiography and was referred to ICA after insuffi-
cient effect on optimal medical therapy, one patient had a
myocardial infarction, and one patient had new angina symp-
toms 1 year after CCTA.
Safety
After a median follow-up of 8 (6–12) months, two deaths,
three cases of nonfatal myocardial infarctions, two cases of
unstable angina requiring revascularization, and no strokes
(13%) had been recorded in 53 patients with obstructive
CAD on CCTA. Three events occurred in patients with a
CT-FFR ≤ 0.80: one non-cardiac death, one nonfatal myocar-
dial infarction associated with medically treated single-vessel
CAD detected on CCTA, and one case of unstable angina due
to in-stent restenosis. Two nonfatal myocardial infarctions oc-
curred in patients with a CT-FFR > 0.80: one patient with
medically treated single-vessel CAD detected by CCTA, and
one patient without obstructive CAD on CCTA. Two events
occurred in patients without performed CT-FFR analyses: one
non-cardiac death and one case of unstable angina in a patient
with 3-vessel disease diagnosed by CCTA before revascular-
ization was performed.
Comparison between CT-FFR and CT-MPI
CT-FFR was performed in 22 out of 29 patients (76%) who
underwent CT-MPI as part of the CRESCENT II trial. CT-
FFR was not calculated in 4 patients with a coronary total
occlusion, 2 patients with insufficient CCTA image quality,
and 1 patient with a disrupted CCTA dataset. After 6–
12 months follow-up, 11 out of 22 patients underwent ICA
of whom 4 patients had high-risk obstructive CAD, 6 patients
Fig. 2 Case example of CT-
derived fractional flow reserve.
Coronary CT angiography
(CCTA), invasive coronary angi-
ography (ICA), and CT-derived
fractional flow reserve (CT-FFR)
of a single patient. CCTA showed
an intermediate stenosis in the
proximal left anterior descending
artery, requiring additional as-
sessment to determine manage-
ment strategy (a). ICA showed a
non-obstructive stenosis in the
proximal left anterior descending
artery (b). The CT-FFR analysis
showed no lesion-specific ische-
mia (CT-FFR > 0.80) (c)
Fig. 3 Proportion of patients requiring additional noninvasive and/or in-
vasive testing for determining management strategy. The proportion of
patients that required additional testing to reach the final management
designation of medical management or revascularization, observed with
the CT strategy and after implementation of CT-derived fractional flow
reserve (CT-FFR), divided in none, one, or two additional tests. CCTA =
coronary CT angiography
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had low-risk obstructive CAD, and 1 patient had no obstruc-
tive CAD. CT-FFR identified 9 out 10 patients with function-
ally significant CAD on ICA, whereas CT-MPI identified 8
out of 10 patients. Moreover, CT-FFR correctly identified all 4
patients with high-risk CAD, whereas CT-MPI missed one
case and under-classified 2 patients as low-risk CAD (< 10%
left ventricle ischemia).
Discussion
In this study, we assessed the potential impact of on-site CT-
FFR on the diagnostic efficiency and effectiveness of a tiered
cardiac CT protocol in patients with a stenosis ≥ 50% on
CCTA. We demonstrate that the implementation of CT-FFR
may change the diagnostic management, with the potential to
expedite the final diagnosis of CAD, diminish the need for
additional testing, and reduce the number of ICAs in patients
with a stenosis ≥ 50% on CCTA.
Diagnostic efficiency
Numerous noninvasive techniques are available for the eval-
uation of patients with suspect CAD, yet none allows for a
complete anatomical and functional assessment of the coro-
nary arteries [14]. Consequently, multiple tests are often re-
quired, both noninvasively and invasively, to determine the
final diagnosis and management strategy in a population that
has a low disease prevalence and benign clinical outcome, as
demonstrated by several recent trials [16, 17]. In the
CRESCENT I and II trials, a tiered cardiac CT approach
mitigated the cost and burden associated with the diagnostic
work-up without limiting the diagnostic performance com-
pared with functional testing [11, 12]. However, CCTA is
limited in the ability to determine which patients might benefit
most from revascularization, and may result in overtreatment
[5, 18, 19]. CT-FFR has the ability to identify a specific cor-
onary lesion that causes ischemia and opens the way to a
treatment strategy at a coronary artery lesion–specific level
without additional imaging [7]. In this study, we showed that,
of the 372 patients who had been randomized to a tiered car-
diac CT protocol, only 53 patients (14%) would have required
CT-FFR analysis to decrease the need for additional testing
from 19 to merely 11% (p < 0.001) in the entire study popu-
lation. This demonstrates that the addition of CT-FFR may
expedite the diagnosis of CAD and reduce the need for addi-
tional testing. Recently published studies with off-site CT-
FFR have shown similar results and demonstrated that CT-
FFR improved the ability of CCTA to identify obstructive
CAD in symptomatic patients referred for ICA [20, 21].
Moreover, there is some evidence to suggest that off-site CT-
FFRmay be cost-effective [22, 23]. However, on-site CT-FFR
techniques are not yet approved for clinical use. Overall, these
findings support the concept that a combined approach of
CCTA and CT-FFR may improve interpretation and evalua-
tion of patients with suspected CAD than CCTA alone.
Medical management
Hemodynamic evaluation of coronary stenoses using an on-
site CT-FFR solution performed by local physicians can re-
duce diagnostic delay [9]. CT-FFR computation through
Fig. 4 Flowchart of initial
management strategy. Detail
breakdown of management
allocation by cardiac CT data
alone and after adding CT-derived
fractional flow reserve (CT-FFR).
ICA = invasive coronary
angiography
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interpretation of anatomical features (based on machine-
learning algorithms) can be performed in several seconds with
similar diagnostic accuracy as complete coronary flow simu-
lations [6]. This has reduced the overall analysis duration sig-
nificantly [24]. However, it should be acknowledge that the
overall duration of the CT-FFR analysis is determined by the
segmentation of the coronary lumen, which strongly depends
on disease complexity and image quality [8, 9]. Current
European guidelines recommend additional functional testing
in patients with ≥ 50% stenosis on CCTA; therefore, we re-
stricted the CT-FFR analysis to those with ≥ 50% stenosis on
CCTA [1]. Moreover, it has been suggested that CT-FFR is
not of incremental value over CCTA in patients with < 50%
stenosis on CCTA, as the vast majority of these lesions are not
hemodynamically significant [20, 25, 26]. However, hemody-
namically significant disease cannot completely be ruled out
in patients with stenosis < 50% and CT-FFR could be valuable
in specific cases. In our study population, CT-FFRwould have
reclassified management in more than half of patients with
obstructive CAD on CCTA. Our reclassification rate (57%)
was slightly lower than in the prospective, multicenter
ADVANCE registry (The Assessing Diagnostic Value of
Non-invasive FFRCT in Coronary Care), since it incorporated
all patients with obstructive CAD on CCTA including the
patients without CT-FFR analysis [27]. Nevertheless, our find-
ings might even overestimate the potential effect of CT-FFR
since CT-MPI was part of the CRESCENT II study protocol.
Our study also showed that the final diagnosis of CAD was
determined without any hemodynamic assessment in 30% of
patients with obstructive CAD on CCTA. Since CT-FFR does
not require any additional testing and radiation, CCTA with
CT-FFR may promote comprehensive anatomically and he-
modynamically coronary assessment of patients with
suspected CAD, allowing compliance with current recom-
mendations supporting use of both anatomic and functional
data in decision-making [15].
Diagnostic effectiveness and safety
Currently practiced diagnostic strategies based on noninvasive
functional testing do not completely achieve their purpose as
gatekeeper to the cath lab, which has resulted in a reported low
diagnostic yield of ICA [28]. Recently published studies have
shown that combining CT-FFR with CCTA could improve the
diagnostic yield of ICA and lower ICA rates in patients re-
ferred for ICA [21, 29, 30]. Moreover, CT-FFR has shown to
be a better predictor for revascularization and MACE com-
pared with CCTA [29, 31, 32]. Our findings represent the first
evaluation of on-site CT-FFR application as part of a tiered
cardiac CT protocol and demonstrate that the implementation
of CT-FFR may improve the diagnostic yield of ICA and
lower ICA rates in patients evaluated for CAD. The ICA rate
would have decreased from 12 to 10% (p = 0.016), compared
with 13% in the functional arms of the CRESCENT trials [11,
12]. These results warrant performance of prospective trials to
assess the effectiveness and safety of implementing CT-FFR
in the management of patients with suspected CAD.
Comparison between CT-FFR and CT-MPI
CT-MPI allows for visualization or measurement of the re-
gional myocardial blood flow during vasodilator-induced hy-
peremia. Several studies have shown similar diagnostic per-
formance between CT-MPI and CT-FFR [26, 33, 34]. Also in
this cohort, CT-FFR performed at least equally well as CT-
MPI, but could not be performed in patients with suspected
total coronary occlusions or insufficient CCTA imaging qual-
ity. More research is needed to establish the respective value
of each respective technique, or potentially combined in a
tiered diagnostic approach to assess patients with suspected
CAD.
Limitations
The observational nature of this study implies that the CT-FFR
findings were not available to the physicians and did not affect
clinical decision-making. We can only project, based on inter-
national guidelines, how physicians would have applied CT-
FFR results had they been available. Additionally, we used an
existing dataset from two trials with minor protocol differ-
ences in order to test our current hypothesis. CT-MPI was
indicated by the CRESCENT II study protocol and could po-
tential overestimate the potential impact of CT-FFR. ICA data
was not available in all patients in these pragmatic clinical
trials.
In conclusion, our study demonstrates that the implemen-
tation of on-site CT-FFR in a tiered cardiac CT protocol im-
proved the diagnostic efficiency and effectiveness in patients
with obstructive CAD on CCTA.
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